Although both in vitro experiments and animal model studies have confirmed the great potential of targeting CD39/CD73/A2AR pathways for cancer treatment, translating these results into clinical practice will require a deeper understanding of how adenosine regulates the cancer microenvironment. Here, ADORA2A is linked to cancer.